Sniderman, Allan D.

ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk

Sehayek, D., Cole, J., Björnson, E., Wilkins, J. T., Mortensen, M. B., Dufresne, L., Pencina, K. M., Pencina, M. J., Thanassoulis, G., & Sniderman, A. D. (2025) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 20

Is hypertriglyceridemia a reliable indicator of cholesterol-depleted Apo B particles?

De Marco, D., Pencina, K., Pencina, M., Dufresne, L., Thanassoulis, G., & Sniderman, A. D. (2023) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 15

Importance of the triglyceride level in identifying patients with a Type III Hyperlipoproteinemia phenotype using the ApoB algorithm

Varghese, B., Park, J., Chew, E., Sajja, A., Brownstein, A., Pallazola, V. A., Sathiyakumar, V., Jones, S. R., Sniderman, A. D., & Martin, S. S. (2021) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 12

Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies

Alam, U., Mathai, S. V., Filtz, A., Kuno, T., Badimon, J. J., Sniderman, A. D., Virani, S. S., Toth, P. P., Shapiro, M. D., Lavie, C. J., et al. (2026) · Current Cardiology Reports

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 4